Anti-Blood Cancer Compound Library

Description: Blood cancers, also called hematologic cancers, occur when abnormal blood cells start growing out of control, interrupting the function of normal blood cells, which fight off infection and produce new blood cells. Most blood cancers start in the bone marrow, which is where blood is produced. There are three main types of blood cancers: leukemia, lymphoma and myeloma, which afflict millions of children and adults every year, and are often deadly.
Blood cancers, also called hematologic cancers, occur when abnormal blood cells start growing out of control, interrupting the function of normal blood cells, which fight off infection and produce new blood cells. Most blood cancers start in the bone marrow, which is where blood is produced. There are three main types of blood cancers: leukemia, lymphoma and myeloma, which afflict millions of children and adults every year, and are often deadly.
Some common blood cancer treatments include stem cell transplantation, chemotherapy, radiation therapy, targeted therapy, immunotherapy or a combination thereof. As we begin to understand the key signaling pathways and molecular drivers of malignant transformation in haematological disorders, new treatment strategies will continue to be developed.
MCE offers a unique collection of 2676 compounds with identified and potential anti-blood cancer activity. These compounds target blood cancer’s major targets and signaling pathways. MCE anti-blood cancer compound library is a useful tool for anti-blood cancer drugs screening and other related research.
MCE Anti-Blood Cancer Compound Library can be supplied as pre-dissolved Solutions or Solid. For pre-dissolved solutions in this library, there are 2621 compounds supplied in 10 mM solution, 52 compounds supplied in 2 mM solution and 3 compounds supplied in 3 mg/mL solution.
For pre-dissolved solutions, 10 mM for compounds with the solubility not lower than 10 mM, 2 mM for compounds with solubility between 2 mM and 10 mM, and 3 mg/mL for compounds with unconfirmed molecular weight and solubility not lower than 3 mg/mL.

Advantages:

• A unique collection of 2676 compounds with identified and potential anti-blood cancer activity for high throughput screening (HTS) and high content screening (HCS).
• Targets include FLT3, Bcr-Abl, JAK, PI3K, PD-1/PD-L1, etc.
• A useful tool for the discovery of anti-blood cancer drugs.
• Bioactivity and safety confirmed by preclinical research and clinical trials. Some have been approved by FDA.
• Structurally diverse, medicinally active, and cell permeable.
• Detailed compound information with structure, IC50, and brief introduction.
• Validated NMR and HPLC to ensure high purity and quality.
• All compounds are in stock and continuously updated.

Formulation: A collection of 2676 anti-blood cancer compounds supplied as pre-dissolved Solutions or SolidSolution:2621 compounds supplied in 10 mM solution,52 compounds supplied in 2 mM solution,3 compounds supplied in 3 mg/mL solution.

Layout: 96-well storage tube or 96-well plate: 1st and 12th column are left empty.384-well plate: the first two columns and the last two columns are left empty.Compounds with different concentrations or dissolved in different solvents will be put on separate plates.This way of layout may increase the number of plates because there could be three solvents and three concentrations. If you have other requirements, please let us know.

Container: 96- or 384-well Plate with Peelable Foil Seal; 96-well Format Sample Storage Tube With Screw Cap and Optional 2D Barcode

• Artikelnummer: MEXHY-L079-2x100
• Hersteller: MedChemExpress
• Hersteller Artikelnummer: HY-L079-2x100
• Green Labware: Nein
• Verpackungseinheit: 2 x 100 μl
• Mengeneinheit: PAK